Geron (GERN)
Markets RYTELO, the only approved telomerase inhibitor, for transfusion-dependent low-risk MDS patients.
$1.25
vs last close−0.06 (−4.71%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 42 days
EPS estimate
−$0.01
Revenue estimate
$60.7M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.04−$0.03−$0.02−$0.03−$0.03−$0.01−$0.02Pending
Estimate−$0.04−$0.04−$0.03−$0.04−$0.03−$0.03−$0.01−$0.01
Surprise0.0%+25.0%+33.3%+18.2%0.0%+66.7%−125.2%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$47.5M$39.6M$49.0M$47.2M$48.0M$51.8M$57.5MPending
Estimate$45.3M$51.8M$47.3M$53.3M$50.4M$50.6M$55.3M$60.7M
Surprise+5.0%−23.6%+3.7%−11.5%−4.8%+2.5%+3.9%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $0.04 | — | — |
| Sep 2027 | $0.02 | — | — |
| Jun 2027 | $0.02 | — | — |
| Mar 2027 | $0.01 | — | — |
| Dec 2026 | $0.00 | — | — |
| Nov 2026 | −$0.01 | — | — |
| Aug 2026 | −$0.01 | −$0.02 | −125.2% |
| May 2026 | −$0.03 | −$0.01 | +66.7% |
| Feb 2026 | −$0.03 | −$0.03 | 0.0% |
| Nov 2025 | −$0.04 | −$0.03 | +18.2% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Jul 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $0.04 | — | — | $99.4M | — | — | — |
| Sep 2027 | $0.02 | — | — | $91.0M | — | — | — |
| Jun 2027 | $0.02 | — | — | $83.5M | — | — | — |
| Mar 2027 | $0.01 | — | — | $77.1M | — | — | — |
| Dec 2026 | $0.00 | — | — | $66.3M | — | — | — |
| Nov 4, 2026 | −$0.01 | — | — | $60.7M | — | — | — |
| Aug 5, 2026 | −$0.01 | −$0.02 | −125.2% | $55.3M | $57.5M | +3.9% | +21.6% |
| May 6, 2026 | −$0.03 | −$0.01 | +66.7% | $50.6M | $51.8M | +2.5% | −4.2% |
| Feb 25, 2026 | −$0.03 | −$0.03 | 0.0% | $50.4M | $48.0M | −4.8% | −11.8% |
| Nov 5, 2025 | −$0.04 | −$0.03 | +18.2% | $53.3M | $47.2M | −11.5% | −5.2% |
| Aug 6, 2025 | |||||||
| May 7, 2025 | |||||||
| Feb 26, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 2, 2024 | |||||||
| Feb 28, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 16, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 9, 2022 | |||||||
| Mar 10, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 16, 2021 | |||||||
| May 10, 2021 | |||||||
| Mar 11, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 28, 2020 | |||||||
| Mar 12, 2020 | |||||||
| Nov 6, 2019 | |||||||
| Aug 1, 2019 | |||||||
| May 2, 2019 | |||||||
| Mar 7, 2019 | |||||||
| Nov 1, 2018 | |||||||
| Jul 31, 2018 | |||||||
| May 10, 2018 | |||||||
| Mar 16, 2018 | |||||||
| Nov 1, 2017 | |||||||
| Aug 9, 2017 | |||||||
| May 9, 2017 | |||||||
| Mar 1, 2017 | |||||||
| Nov 3, 2016 | |||||||
| Aug 3, 2016 | |||||||
| May 5, 2016 | |||||||
| Feb 25, 2016 | |||||||
| Nov 5, 2015 | |||||||
| Aug 5, 2015 |